RxDoctor Payments Data

Britt Stone, MD

Neurology · Nashville, TNNPI 1548494289

Payments from drug & device makers

$74,658in general payments, 2019–2025

Across 197 payments — averaging $378.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$68K
  • Medtronic$2K
  • Amneal Pharmaceuticals LLC$2K
  • Neurocrine Biosciences, Inc.$711
  • Acadia Pharmaceuticals Inc$310
  • Amgen$294
  • plus $654 from 8 others

What the payments were for

  • Consulting fees$8,16811%
  • Speaking & faculty fees$50,73868%
  • Travel & lodging$9,67213%
  • Food & beverage$6,0808%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Boston Scientific128$68,357
Medtronic(2 entities)35$2,386
Amneal Pharmaceuticals LLC3$1,947
Neurocrine Biosciences, Inc.6$711
Acadia Pharmaceuticals Inc4$310
Amgen3$294
Supernus Pharmaceuticals, Inc.2$280
AbbVie(2 entities)6$142
AstraZeneca3$73
UCB, Inc.2$49
Lundbeck LLC1$37
Neurelis, Inc.2$33
Bayer1$23
Cycle Pharmaceuticals Inc1$18

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$74,658 in reported general payments places this provider in the 80th percentile of 361 neurology providers in Tennessee.

See all neurology providers in Tennessee

Medicare billing

Part B allowed, 2024
$70,250
Medicare patients
314
Services billed
938

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IngrezzaValbenazine Tosylate65$408,981
AustedoDeutetrabenazine44$337,924
NuplazidPimavanserin Tartrate52$250,757
RytaryCarbidopa/Levodopa45$98,499
InbrijaLevodopa11$53,517
Carbidopa-LevodopaCarbidopa/Levodopa577$33,764
Tetrabenazine26$23,460
Carbidopa-Levodopa ErCarbidopa/Levodopa217$16,757
NeuproRotigotine15$15,457
Droxidopa17$13,896
AmantadineAmantadine Hcl110$8,231
Entacapone29$8,182
Selegiline Hcl31$4,967
Primidone126$4,431
Carbidopa-Levodopa-EntacaponeCarbidopa/Levodopa/Entacapone13$3,155

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Neurocrine Biosciences, Inc.Ingrezza$711$408,98165 claims
Acadia Pharmaceuticals IncNuplazid$310$250,75752 claims
Amneal Pharmaceuticals LLCRytary$1,947$98,49945 claims
UCB, Inc.Neupro$49$15,45715 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 361 neurology providers in Tennessee.

Other neurology in Nashville

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →